drugset / Trial / NCT04443868

Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection

NCT04443868

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.

Timeline

Start
2021-01
Primary completion
2021-04
Completion
2021-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 14.4 ppm Intranasal
Subject Nitric Oxide Other / unclassified 240 ml Intranasal

Indications